Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018087271) TRUNCATED VON WILLEBRAND FACTOR POLYPEPTIDES FOR EXTRAVASCULAR ADMINISTRATION IN THE TREATMENT OR PROPHYLAXIS OF A BLOOD COAGULATION DISORDER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/087271 International Application No.: PCT/EP2017/078840
Publication Date: 17.05.2018 International Filing Date: 10.11.2017
IPC:
A61K 38/36 (2006.01) ,A61K 38/37 (2006.01) ,C07K 14/755 (2006.01) ,A61P 7/04 (2006.01) ,A61K 36/36 (2006.01) ,A61K 36/37 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
36
Blood coagulation or fibrinolysis factors
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
36
Blood coagulation or fibrinolysis factors
37
Factors VIII
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
745
Blood coagulation or fibrinolysis factors
755
Factors VIII
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7
Drugs for disorders of the blood or the extracellular fluid
04
Antihaemorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18
Magnoliophyta (angiosperms)
185
Magnoliopsida (dicotyledons)
36
Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18
Magnoliophyta (angiosperms)
185
Magnoliopsida (dicotyledons)
37
Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
Applicants:
CSL BEHRING LENGNAU AG [CH/CH]; Industriestrasse 11 2543 Lengnau BE, CH
Inventors:
PESTEL, Sabine; DE
RAQUET, Elmar; DE
WEIMER, Thomas; DE
Agent:
LUDWIG, Holger; DE
BINSACK, Beate; DE
HAUSER, Hans-Peter; DE
PETER, Beate; DE
Priority Data:
16198497.611.11.2016EP
Title (EN) TRUNCATED VON WILLEBRAND FACTOR POLYPEPTIDES FOR EXTRAVASCULAR ADMINISTRATION IN THE TREATMENT OR PROPHYLAXIS OF A BLOOD COAGULATION DISORDER
(FR) POLYPEPTIDES DU FACTEUR DE VON WILLEBRAND TRONQUÉ POUR UNE ADMINISTRATION EXTRAVASCULAIRE DANS LE TRAITEMENT OU LA PROPHYLAXIE D'UN TROUBLE DE LA COAGULATION DU SANG
Abstract:
(EN) The invention pertains to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment or prophylaxis of a blood coagulation disorder, said treatment or prophylaxis comprising administering the recombinant polypeptide and a Factor VIII protein (FVIII) extravascular to a subject having a blood coagulation disorder, wherein said recombinant polypeptide is capable of binding to said FVIII, and wherein the molar ratio of the recombinant polypeptide to be administered to the FVIII to be administered is higher than 50.
(FR) L'invention concerne un polypeptide recombinant comprenant un facteur von Willebrand (VWF) tronqué destiné à être utilisé dans le traitement ou la prophylaxie d'un trouble de la coagulation sanguine, ledit traitement ou prophylaxie comprenant l'administration extravasculaire du polypeptide recombinant et d'une protéine du facteur VIII (FVIII) à un sujet ayant un trouble de la coagulation du sang, ledit polypeptide recombinant étant capable de se lier audit FVIII, et le rapport molaire du polypeptide recombinant à administrer au FVIII à administrer étant supérieur à 50.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)